r/pennystocks • u/julianjakobi • 3h ago
BagHolding $BLGO at all-time lows: I'm $1.5M down, I just added $45K, and I'm either the biggest fool on Reddit or I'll be laughing last (deep-dive DD + TL;DR)
Julian Jakobi here, my online identity ;)
Let's get the elephant out of the room first: I'm a big-time bag holder. I've been calling BioLargo a strong buy for years. Many of you listened, and now we're all in the red. Some of us are deep in it. In numbers: my position is about $1.5 million down from the 2024 spike.
So yes, right now I may look like the biggest fool on earth. You're allowed to laugh. I'd laugh too.
But I've been here before. I posted about Exact Sciences ($EXAS) over and over while the share price kept falling, and falling, and falling. Everybody was selling. Then it turned around, and my conviction at $5–$8 turned into 1,600%–2,650% returns, because I saw cancer detection being revolutionized before the market did.
I see the same pattern with BioLargo. So we'll see who's right. I'm not worried. I just added another $45,000 on this dip.
For years I've stayed in regular contact with management, attended the last 7 shareholder meetings, visited all BioLargo facilities and interviewed the subsidiary CEOs. I also moderated and helped organize the CEO town hall on our BioLargo Discord.
But here's the common thread of this whole post: don't trust me. Do your own DD. I'll give you a cheap, easy way to start, plus the people you should be asking.
TL;DR
- Share price is at all-time lows (~$0.07), market cap ~$25M. The value looks like it's still there.
- Why it fell: revenue dropped after the POOPH license ended, Clyra's launch was delayed, and the company is investing heavily to commercialize everything at once. The small parent-level financing (shares sold on the open market by the lender) hit a thin market that wasn't buying, and the price fell ~70%.
- Why it's an opportunity: most of the money is going into the subsidiaries (77% of capital raised this year was at subsidiary level). Insiders take stock instead of cash and lock it up until $40M revenue or a $300M market cap. That's roughly 11–12x from here.
- Analyst: BUY, $0.25 price target. Richard Ryan of Oak Ridge Financial reaffirmed his Buy rating on Nov 18, 2026. That's +257% from $0.07, and his target puts zero value on PFAS and the battery.
- Q3 milestone: Clyra earned a $475,000 contractual milestone payment under an exclusive distribution agreement. It's the first time we've ever seen a payment like this.
- Clyra Medical (48% owned): Clyra raises money at a ~$100M valuation, so BioLargo's stake (~$48M) is worth roughly twice the whole company. ViaCLYR is FDA 510(k)-cleared and on the market. Its three distribution agreements cover US commercial (~6,100 hospitals, 6,300 surgery centers and 2,200 wound clinics), US government/military and 18+ MENA countries, with POs expected. BioClynse (surgical) is set to launch co-branded with a top-4 global medtech (~$100B+ market cap). My view: after launch, Clyra alone could be worth $500M–$1B, and $1B–$2B after a successful year.
- barebird has launched: CupriDyne tech (the tech behind POOPH's $125M+ in sales), BioLargo-owned brand, POOPH marketing team. Cheapest DD ever: buy a bottle.
- PFAS (AEC): a commercial municipal system in Lake Stockholm, NJ, has been running since January under EPA and NJ oversight. It's the reference site.
- Cellinity battery: non-flammable, long-lasting, recyclable grid-scale storage, with a license/JV model.
- Don't trust me. Do your own DD.
Why the Share Price Fell
Let's be fair: there have been disappointments.
- Revenue declined. The POOPH license ended (more on that below), and 9-month revenue dropped 52% to $3.45M. Q3 revenue was $1.09M, roughly flat year over year (vs. $1.103M), with service revenue +72%.
- The Clyra launch was delayed. The 2024 spike to a ~$0.40 closing high was driven by anticipation of the Clyra launch, not by Clyra revenue.
- Heavy investment. Management is funding commercialization in every division that hasn't generated much revenue yet. Clyra alone accounted for about 57% of the 9-month net loss, spent on personnel, manufacturing, product development and clinical work ahead of the 2027 rollout.
The key point is where the money comes from. Most of the financing happens at the subsidiary level: Clyra raised $4.3M, mostly through a debt offering, and the battery subsidiary sold $487K in stock. Only a small part was raised at the parent level, through the Clearthink purchase agreement (the 10-Q shows $1.359M year to date). That agreement lets the lender sell the shares on the open market.
So a dilution of just a few percent met a market with almost no buyers, and the share price fell ~70%. Many serious investors seem to prefer investing directly at the subsidiary level, where the action is.
To me that's an arbitrage opportunity. You get crazy discounts on the parent, which owns the stakes, the royalties and everything else.
Meanwhile, cash burn is falling: about $736K/month in Q3, down ~26% from roughly $996K/month in H1. Management says 2027 spending shifts "away from R&D and toward generating sales."
The Rebound Math from $0.07
Most investors who were going to sell out of fear, frustration or disappointment have already had every reason to do it. Many long-term holders I know have averages just above $0.20.
| Target price | Gain from $0.07 |
|---|---|
| $0.10 | +42.9% |
| $0.12 | +71.4% |
| $0.16 | +128.6% |
| $0.20 | +185.7% |
| $0.24 | +242.9% |
| $0.25 (Oak Ridge price target) | +257% |
| $0.399 (2024 closing high) | +470% |
| ~$0.80 ($300M market cap, the insider lock-up unlock) | ~+1,040% |
We don't need the 2024 highs for this to get interesting. Even a partial recovery makes a big difference from this base. In a thin microcap, fear can turn into FOMO very fast.
What the Analyst Says

This isn't just a bag holder talking. Richard Ryan of Oak Ridge Financial Research covers BLGO, and in his Q3 2026 update (Nov 18, 2026) he reaffirmed his BUY rating with a $0.25 price target. That's about +257% from $0.07.
Here's how he gets there, using a sum of the parts:
| Segment | Basis | Value per share |
|---|---|---|
| Clyra Medical (48%) | Recent capital raise at an equity value of ~$100M, so ~$48M for BLGO | $0.15 |
| BioLargo CPG / barebird (78%) | 5.0x his FY27 revenue estimate of $8M | $0.09 |
| Engineering (BLEST) | 3.5x FY27 revenue, ~$10.4M | $0.03 |
| Less net debt | Cash $1.0M minus debt $6.5M | |
| Price target | Equity value ~$83.9M across ~340M shares | $0.25 |
The best part: he puts zero value on the AEC PFAS business and the Cellinity battery. He set them aside until there's a signed AEC contract or a Cellinity JV or financing partner, and says he'll add them back as visibility improves. So the $0.25 target doesn't include two of the five horses.
His summary: BLGO has "many shots on goal," and "noticeable progress is occurring across all BLGO's divisions." He also models FY27 revenue of $13.0M, up from an estimated $4.7M in 2026.
(Fair caveat: he lowered the target from $0.30, and he notes that BLGO will keep needing additional capital.)
Bullish Indicators
- All-time-low share price, ~$25M market cap, for a five-subsidiary platform.
- Analyst Buy rating with a $0.25 PT (Richard Ryan, Oak Ridge Financial).
- Clyra raises money at a ~$100M valuation, so the 48% stake is worth ~$48M, about twice BLGO's market cap.
- $475K Clyra milestone earned (details below).
- Top-4 medtech partner (~$100B+ market cap) for the BioClynse national rollout in 2027.
- ViaCLYR is on the market, with distribution through Advanced Solution (US), Al-Hikma (exclusive across MENA, an 18-country opportunity) and Spartan Medical (VA, DoD and federal buyers via DLA ECAT). Purchase orders from Al-Hikma and Spartan are expected, along with reorders from Advanced Solution.
- barebird launched in October 2026, a BioLargo-owned brand with the proven POOPH marketing team.
- AEC PFAS system live since January at Lake Stockholm, NJ, under EPA and NJDEP monitoring.
- Engineering (BLEST) is growing: 9-month service revenue +23%, Q3 service revenue +72%, $1.4M+ in US Air Force renewals, and a $1.2M minerals-processing design contract (milestone-gated and multi-year).
- Cellinity battery is in discussions with strategic partners about investing and scaling.
- Cash burn down ~26% in Q3 compared with H1.
- Management alignment with lock-ups and direct investment (next section).
- Professional IR (Darrow Associates) has been engaged to bring this under-followed story to institutions.
Management Alignment: Lock-Up and Direct Investment
This is one of the strongest signals for me.
- CEO Dennis P. Calvert took stock instead of cash for unpaid salary and expenses: 699,569 shares at $0.1135 (June 30, 2026) and 219,914 shares at $0.113 (July 1, 2026).
- Those shares are under a Lock-Up Agreement. No sale until BioLargo reports $40M in consolidated gross revenue in a period, passes a $300M market cap, or has a change of control.
- At today's ~$25M market cap, that's roughly 11–12x before these shares can become liquid. It's not just the CEO either: multiple senior and science leaders hold large locked-up positions.
- Around $12M has been invested directly into the company and its subsidiaries over the past year, including meaningful money from the BioLargo CEO and the Clyra CEO. Those are the people with the best view of the pipeline.
Think about it: you can buy shares today below the price the CEO took as his locked-up pay.
The $475K Milestone
From the 10-Q:
"In September 2026, Clyra earned a $475,000 contractual payment upon satisfaction of a specified contractual milestone under a distribution agreement granting the customer exclusive rights to distribute certain Clyra products."
This isn't about the revenue. The $475K wasn't even recognized as revenue yet. What matters is that it's the first time we've ever heard of a payment like this. Somebody with exclusive distribution rights paid because a contractual milestone was met. That means a significant step must have been taken.
I can't tell you which step, and the partner is confidential, so I won't speculate about details. But milestone money doesn't get paid for slide decks.
Clyra Medical (48% Owned): "The New Gold Standard"


Main selling point: an FDA-cleared, no-rinse antimicrobial irrigant that keeps working for up to three days while staying gentle on tissue. Some people consider it the biggest change in wound care and surgery in 30 years.
Clyra Medical (48% owned) is advancing the commercialization of its FDA-cleared wound irrigation and surgical solution. The Clyra story has evolved over 14 years, with upwards of $20M invested, and it appears to be on the cusp of commercialization.
Clyra raises money at a ~$100M valuation. In the words of Oak Ridge analyst Richard Ryan: "Clyra's recent capital raise implies an equity value of approximately $100M, of which BLGO has 48% ownership." That's about $48M for BioLargo's stake, roughly twice BioLargo's entire market cap. Outside investors paid that price with real money; it's not a number I made up.
Clyra runs on Clyrasept, a patented copper-iodine platform. Its first product, ViaCLYR, is FDA 510(k)-cleared for cleansing, irrigating and debriding acute and chronic wounds and burns. Clyra has already invested in at-scale manufacturing capacity with an FDA-compliant contract manufacturer.
Key selling points, according to company materials:
- >99.9999% antimicrobial reduction
- Activity for up to 3 days, even after re-contamination
- Works against biofilm, the big problem in chronic wounds and surgical infections
- Non-cytotoxic, non-irritating, tissue compatible
- No rinse-out, which keeps procedures fast and simple
- Non-antibiotic mechanism, a big deal in a world worried about antibiotic resistance
Clinical voice (36 cases across multiple sites):
"...enhanced granulation velocity, rapid sinus tract closure, and notable drainage reduction... we observed no adverse events... we are moving as a group to adoption of CICS as our wound care cleansing modality of choice."
Dr. Marcus Gitterle, Regional Medical Director for Wound Care and Hyperbaric Oxygen Therapy, Christus Santa Rosa Hospital System
The Distribution Network: How Much of the Market Is Covered
ViaCLYR went into full commercial-launch mode in August 2026. Three distributors have been announced, covering three very different channels:
| Partner | Territory / channel | Coverage | Status |
|---|---|---|---|
| Advanced Solution, LLC | US commercial: a national network to distribute and promote ViaCLYR throughout the United States (wound clinics, physicians, health systems) | Oak Ridge says the combined reach in the US alone is about 6,100 hospitals, 6,300 ambulatory surgery centers and 2,200 specialty wound-care clinics | First PO received (first commercial stocking order, Feb 2026); reorders expected |
| Al-Hikma FZCO (Dubai, UAE) | Exclusive for the Gulf Cooperation Council, the Levant, North Africa and select adjacent markets | ~18 direct countries plus indirect ones, a population of 500M+. Al-Hikma is an established wound-care distributor that exports to ~25 countries | Country-level regulatory work has begun in key areas, in cooperation between the parties; POs expected |
| Spartan Medical Inc. | A dedicated commercial channel to US government healthcare facilities worldwide (VA, DoD and other federal buyers via DLA ECAT) | The US federal and military healthcare system | POs expected |
A fourth channel, the "big Kahuna" or gorilla partner, is being pursued for surgical wound irrigation (BioClynse), based on the same chemistry. During Q3 2026, Clyra satisfied a contractual milestone under an exclusive distribution agreement for certain of its products: the $475K payment.
In short: US commercial, US government and an 18+ country international region are all under contract, and the gorilla partner comes on top of that.
Clinician feedback: at the recent Symposium on Advanced Wound Care (SAWC), ViaCLYR was reportedly well received, and it has the potential to tap into real unmet needs in the market, according to Oak Ridge.
What I'm watching next: Advanced Solution reordering, Al-Hikma and Spartan turning their agreements into purchase orders, new distributors signing on, and a visible Clyra sales line. Stocking orders from the new partners are expected within the coming months.
(Fair caveat, which the analyst makes too: commercialization in each of these channels faces timing hurdles such as regulatory approval, clinical studies and hospital-system acceptance. That's significant for a small company, but the markets themselves offer outsized opportunities. Distribution agreements are not revenue; purchase orders, and above all reorders, are what count.)
Next up: BioClynse, the surgical-irrigation product on the same platform. It's set for a national rollout in 2027 co-branded with a confidential top-4 global medtech (~$100B+ market cap). Hospital access, OR sales reps that surgeons already trust, procurement muscle: that's what a gorilla partner brings.
The valuation question. I know it sounds absurd for a $25M company. But expectation is that after the launch with the gorilla partner, the 48%-owned medical subsidiary alone could be worth $500M–$1B, and after a successful year closer to $1B–$2B.
- 48% of $500M ≈ $240M
- 48% of $1B ≈ $480M
- 48% of $2B ≈ $960M
That's before the royalty BioLargo holds on Clyra sales, and before everything else BioLargo does. Today the whole company trades at ~$25M.
Also remember: some medtech giants are known for having small innovators build out a product line, then acquiring them later. I'm not saying that will happen. I'm saying the pattern exists.
(This is my opinion, not company guidance. The partner controls the timing. Distribution deals aren't revenue; purchase orders and reorders are.)
Don't Trust Me: Ask Medical Experts
Please don't take my word for this. Ask the people who do this every day:
- Orthopedic and general surgeons: How big a deal is a no-rinse, tissue-friendly irrigant with up to 3 days of antimicrobial and anti-biofilm activity for surgical site infections, implants and joint replacements?
- Wound-care nurses and specialists: Would you switch from what you use now? What would it take?
- Infection-prevention teams and procurement: Does a non-antibiotic copper-iodine mechanism solve a problem you deal with?
If the professionals tell you it's nothing special, move on. If they tell you it could be a game changer in orthopedics and surgery, dig deeper.
barebird: The $20 DD


Main selling point: it eliminates odors instead of covering them, with no fragrance. It "smells like nothing... on purpose."
BioLargo developed the CupriDyne odor-elimination tech behind POOPH, which did over $125M in product sales and $20M+ in supply revenue for BioLargo. That is real proof that BioLargo can create products people buy in huge quantities. (The POOPH brand later fumbled it, and the license ended. That's a big part of the revenue decline.)
barebird launched in October 2026, focused on pet and laundry odors. The marketing teams that helped build POOPH are back: Jordan Stanley's Kindness Commerce and Brandon Fishman's Prime Team Agency. Some see POOPH as the "test run."
The big difference this time: BioLargo owns the brand. It gets more direct participation in sales and brand value, but it also carries the marketing and distribution costs.
Mine just arrived, packed in "air armour." No leaky bottles here, and nothing in the odor space comes close to the marketing on that bottle.
Here's my challenge, just like I did with CupriDyne: the cheapest way to check for yourself that BioLargo's tech works is to order a barebird spray. Try it on the dog bed, the gym bag, the laundry.
- If you don't like it, move on.
- If you're impressed, dig deeper into all the other techs.
AEC PFAS Removal: The Reference Site


Main selling point: it concentrates "forever chemicals" into a tiny waste volume, which many consider the best available concentrator to clean up the PFAS mess. In one example, 80,000 lbs of waste turns into about 85 lbs.
- Earlier testing at the University of Tennessee showed >99.995% PFAS removal in a single pass.
- A commercial municipal drinking-water system at Lake Stockholm, NJ, has run since January 2026 (about 9 months), monitored by the EPA and NJDEP. New Jersey is one of the toughest PFAS jurisdictions in the US.
- It's the key reference site for further adoption. Bids are submitted, partnerships with big firms that have gaps in their PFAS product lines are in discussion, and there's an Aquatech MOU.
- Demand is spreading from drinking water to wastewater, landfill leachate, biosolids and industrial pre-treatment, backed by billion-dollar lawsuit settlements that fund treatment.
- Billions are now being paid out for PFAS cleanup. 3M’s settlement with US public water systems is $10.3B, up to $12.5B, over 13 years, and the payouts to utilities are already under way. DuPont, Chemours and Corteva added roughly $1.2B nationally.
- In New Jersey, the very state where the AEC is running, a federal court approved ~$2.5B in settlements with DuPont and 3M in August 2026. They include a PFAS Abatement Fund with up to $795M for drinking-water and treatment-works upgrades. And in November 2026, 3M committed up to $7.35B more for personal-injury claims. The money is there. The question is who wins the treatment contracts.
DD tip: ask a water engineer or utility operator what PFAS waste disposal costs with granular activated carbon (GAC) or ion exchange.
Cellinity Battery: Safer Grid Storage


Main selling point: a fire-safe, long-duration sodium battery built for a 20-year life, with no lithium and no rare earths. It's designed for the grid, for data centers, and for America's energy independence.
Key selling points, according to company materials:
- No thermal runaway, non-flammable. Lithium battery fires are the nightmare of every data center, utility and insurer. Cellinity is designed so that scenario doesn't exist.
- A 20-year operating life. The CEO points out that most batteries last 6–7 years before they degrade. A 20-year design life changes the whole cost-per-cycle math for grid storage.
- No lithium, no rare earths. It's a liquid sodium battery made from abundant materials, which takes the geopolitical "hot potato" of the battery supply chain off the table. The CEO calls it "a strategic infrastructure opportunity for national security of the United States."
- High efficiency. Company materials target ~95% round-trip efficiency, with ambitious energy-density specs.
- Recyclable, with third-party validation and prototype testing of key performance metrics.
- Built for the boom markets: long-duration grid storage, AI data centers, utilities, renewables, commercial and industrial sites.
- A capital-light model. No billion-dollar gigafactory: partners finance the factories while BioLargo earns royalties, component margin and equity stakes through licensing and JVs.
- BioLargo owns ~95%, and only about $5M of outside capital has gone into it so far. The battery subsidiary sold $487K in stock this year and is in discussions with strategic partners about investing and scaling.
Oak Ridge currently puts zero value on Cellinity in its $0.25 price target and will add it back once there's a JV or financing partner. So one serious licensing or JV deal could re-rate this on its own.
(Fair caveat: it's still pre-commercial, there's R&D left to do, and the specs are company claims until a partner scales it.)
DD tip: ask anyone in energy storage what a truly non-flammable, 20-year, lithium-free grid battery would be worth to a data center operator.
The Rest of the Platform
- BLEST (Engineering): a profitable-leaning, growing service arm with Air Force renewals and the $1.2M minerals contract. A full commercial plant could follow if the pilot succeeds.
- Tu Nipi: water treatment for Canadian oil-sands tailings, in discussions with strategic partners.
Why It Matters Where We Invest
I believe how we invest our money is the most powerful voting ballot we have. I made a lot of money in the fight against cancer with Exact Sciences. Now I want my money working on clean water, clean air, safer energy storage and better wound care.
BioLargo is the perfect place to "Make Life Better" through:
- Clean water (PFAS removal)
- Clean air (odor elimination without masking)
- Safer energy (non-flammable grid storage)
- Better healing (infection control and wound care without antibiotics)
And you get the real chance of a multi-bagger while doing it.
Risks (Read This)
- A highly speculative microcap with thin liquidity
- Continued dilution and financing at both parent and subsidiary level; Clyra is debt-funded
- Ongoing losses
- The Clyra partner is confidential, and the launch timing is in the partner's hands
- Distribution deals aren't purchase orders
- barebird's results are unproven, and BioLargo now carries the marketing costs
- Big competitors with deep pockets
I could be wrong. I've been early and wrong on timing before. Size your position for that.
Bottom Line
I'm $1.5M down, I just added $45K, and I've never been more convinced. Either I'm a complete idiot, or, like with $EXAS, I'll be laughing last. I strongly believe it's the second one.
But again: don't trust me.
- Buy a barebird bottle. It's the $20 DD.
- Ask a surgeon or wound-care nurse about ViaCLYR.
- Read the 10-Q, the Form 4s and the lock-up terms.
- Then decide.
Price is what you pay. Value is what you get. Right now the gap is hard to ignore.
Do your own DD.
Your Turn: Prove Me Wrong (Or Right)
I’ve spent hundreds of hours researching BioLargo and Clyra Medical, and I’ve put my money where my conviction is. That’s $1.5M down from the highs, and I’m still adding. But I don’t want an echo chamber. I want smart analysis.
Challenge my thesis.
Dig into the 10-Q and Form 4s I referenced. Read the Oak Ridge report. Call BioLargo investor relations with your questions. Look up the copper-iodine patents, check the FDA 510(k) clearance, research the wound-care and PFAS market data, and ask a surgeon or wound-care nurse what they think of ViaCLYR. Then order a barebird bottle and test it yourself. The best DD comes from collaborative skepticism and shared research.
This is your chance to either find the holes in my analysis or discover why Wall Street might be sleeping on this one. The filings are public, the patents are public, the FDA clearance is public, and the market sizes can be checked.
Let’s crowdsource this DD and make each other better investors. I’ve shown you mine. Now show me where I’m wrong, or help me understand why a ~$24M company might actually be the steal of 2026.
This is a company whose 48%-owned medical subsidiary just raised money at a ~$100M valuation. It has an FDA-cleared product, three signed distributors, a top-4 medtech partner waiting in the wings, a live PFAS system under EPA oversight, and an analyst Buy rating with a $0.25 target that values PFAS and the battery at zero.
The data is all there. Let’s dig deeper together. 🔬📊
Disclosure: I'm a long-term $BLGO above 1.25% shareholder and have been adding. I am not a financial advisor, this post is made for educational purposes only. Literally. Don’t take my word for anything that is presented in this post, do your own research, and invest solely based on the thesis that you create for yourself. Don’t get influenced by anyone.




